How diabetes damages the cornea
A Novel Pathogenic Pathway for Diabetic Keratopathy
This research looks at whether boosting a protein called PPARα (for example with the drug fenofibrate) can protect the cornea and its nerves in adults with diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of North Texas Hlth Sci Ctr NIH-funded |
| Lab location | 1 site (Fort Worth, United States) |
| Project ID | NIH-11259566 on NIH RePORTER |
What this research studies
Researchers will examine corneal tissue from people with diabetes and from laboratory models to understand why diabetic corneas lose nerve fibers and heal poorly. They will measure PPARα levels, test how losing PPARα affects production of nerve-supporting factors, and use fenofibrate in cells and animals to see if it prevents damage. Laboratory studies will also look at inflammation, oxidative stress, and molecular pathways linking PPARα to corneal nerve health. The findings are intended to point toward treatments that protect corneal nerves and improve healing in people with diabetes.
Who could benefit from this research
Good fit: Adults with diabetes who have corneal symptoms—such as slow wound healing, reduced corneal sensitivity, or diagnosed diabetic keratopathy—would be the most relevant candidates for related clinical work.
Not a fit: People without diabetes or those whose corneal problems are due to other causes (like trauma or infection) are unlikely to benefit from this specific line of research.
Why it matters
Potential benefit: If successful, this work could lead to treatments that preserve corneal nerves, speed healing, and reduce vision problems caused by diabetic keratopathy.
How similar studies have performed: Large clinical trials showed fenofibrate helps diabetic retinopathy and early lab and animal studies support PPARα’s protective effects on corneal nerves, but direct clinical proof for corneal benefit is still limited.
Where this research is happening
Fort Worth, United States
- University of North Texas Hlth Sci Ctr — Fort Worth, United States (Active)
Researchers
- Principal investigator: Karamichos, Dimitrios — University of North Texas Hlth Sci Ctr
- Study coordinator: Karamichos, Dimitrios
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.